Repurposed arthritis drug did not significantly improve severe COVID-19 pneumonia

(University of California - San Diego) A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news